How Lumitex Used Early-Stage R&D to De-Risk a Complex Medical Device Concept.
Acute Respiratory Distress Syndrome, or ARDS, is a life-threatening inflammatory lung condition that can cause severe hypoxemia, impaired gas exchange, mechanical ventilation, prolonged ICU care, and high mortality [1][2][3]. Because ARDS is clinically urgent and biologically complex, potential new therapies must be evaluated carefully across clinical need, technical feasibility, treatment timing, dose response, and safety.
Lumitex explored whether Photobiomodulation (PBM), could play a role in supporting treatment for ARDS. The project began with a clinical question: could targeted red and near-infrared light influence inflammatory response and respiratory function in a way that could eventually translate into a therapeutic medical device platform? [4][5][6]




